TARO-PALBOCICLIB 125 MG
PALBOCICLIB : 125 MG · DIN 02547651 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-PALBOCICLIB?
TARO-PALBOCICLIB 125 MG contains PALBOCICLIB : 125 MG. It is listed in the Health Canada Drug Product Database under DIN 02547651, held by TARO PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Sep-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-PALBOCICLIB used for?
Treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after prior endocrine therapy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02547651 |
|---|---|
| Brand name | TARO-PALBOCICLIB |
| Generic / active ingredient | PALBOCICLIB : 125 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EF01 PALBOCICLIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Sep-2024 |
How is it administered?
125 mg once daily for 21 consecutive days followed by 7 days off (28-day cycle). Taken with or without food. Swallow whole. Dose adjustments required for toxicity.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refer to section 11 in full monograph).
How is it supplied?
Box containing 3 weekly blister packs of 7 tablets each (21 tablets total).
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warning: Neutropenia. Other: Interstitial lung disease/pneumonitis (can be fatal), venous thromboembolism, and infections. Prescribed by a qualified physician.
What can be used instead?
Other Canadian products sharing ATC code L01EF01 PALBOCICLIB. 9 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IBRANCE | 100 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02493543 |
| IBRANCE | 125 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02493551 |
| IBRANCE | 75 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02493535 |
| PMS-PALBOCICLIB | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02552132 |
| PMS-PALBOCICLIB | 125 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02552140 |
| PMS-PALBOCICLIB | 75 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02552124 |
| TARO-PALBOCICLIB | 100 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02547643 |
| TARO-PALBOCICLIB | 75 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02547635 |
| IBRANCE | 100 MG | CAPSULE | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02453169 |
| IBRANCE | 125 MG | CAPSULE | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02453177 |
Who else supplies PALBOCICLIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PALBOCICLIB appears in 89 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.